The next leap forward in cancer immunotherapy

ABOUT ASGARD THERAPEUTICS

An important hallmark of cancer is the ability to evade the immune system. Asgard Therapeutics has the ambitious goal to establish dendritic cell reprogramming as an entirely new approach to unleash the immune system against cancer.

Learn more

OUR SCIENCE

Asgard is developing TrojanDC, the world’s first cancer immunotherapy based on direct cell reprogramming, forcing cancer cells to become immunogenic again.

OUR TEAM

Asgard was created by some of the brightest researchers in the cell reprogramming field. In the end, we hope our work will make a measurable impact in patients’ life. Meet our team